Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when CP-1C crosses your target, drops, or sets a new tracked low—without daily noise.

Price scopeAlert meTarget per mg

$/mg

Confirmed Weekly Peptide Intel email

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.

Public product evidence205 certificate records mentioning this compound or product name106 provider-linked · 171 exact product matches

Status

Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Research area

Metabolic / incretin research

This profile is grouped by its dominant research area, not by vendor shelf placement.

Aliases

No major aliases are tracked for this profile yet.

Signal depth

Medium

No FDA label signal · 44 trials · 96 PubMed results

Promising

Research evidence

Cagrilintide has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Cagrilintide has 20 name-matched clinical trials (highest phase: Phase 3) and 96 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results.

Human data

Phase 3

Trial quality

Large RCT

Outcomes

Clinical outcomes

Replication

Meta-analysis

Literature

Top-tier journals

PHASE3 · RandomizedA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor PHASE3 · RandomizedA Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight PHASE3 · RandomizedWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide The Lancet · 319 citationsEfficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial The Lancet · 311 citationsSafety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial The Lancet · 259 citationsOnce-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What cagrilintide is

Cagrilintide is a long-acting amylin analogue being studied in obesity-focused drug development. It is commonly mentioned alongside semaglutide because combination strategies are a major theme in the metabolic-drug pipeline.

Why it matters

It expands the library beyond GLP-1-only thinking. If someone is trying to understand the next layer of obesity pharmacology, cagrilintide is one of the key names to know.

Regulatory context

Cagrilintide is not FDA approved in the United States. It belongs in the investigational bucket rather than the approved-drug bucket.

Practical reading note

Because cagrilintide often appears next to semaglutide or blend products in vendor catalogs, it is useful to separate the research narrative from branded, labeled prescription-drug status.